Pacific Biosciences
Biotechnology company manufacturing systems for gene sequencing and real-time biological observations.
Launch date
Employees
Market cap
CAD669m
Enterprise valuation
CAD1.2b (Public information from Sep 2024)
Share price
$2.04 PACB
Menlo Park California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 78.9m | 131m | 128m | 201m | 167m | 215m | 285m |
| % growth | (13 %) | 65 % | (2 %) | 56 % | (17 %) | 28 % | 33 % |
| EBITDA | (102m) | (178m) | (297m) | (251m) | (312m) | (163m) | (99.7m) |
| % EBITDA margin | (130 %) | (136 %) | (232 %) | (125 %) | (186 %) | (76 %) | (35 %) |
| Profit | 29.4m | (181m) | (314m) | (307m) | (372m) | (198m) | (157m) |
| % profit margin | 37 % | (139 %) | (245 %) | (153 %) | (222 %) | (92 %) | (55 %) |
| EV / revenue | 57.2x | 33.4x | 15.4x | 14.4x | 5.3x | 4.3x | 3.2x |
| EV / EBITDA | -44.1x | -24.5x | -6.6x | -11.5x | -2.8x | -5.6x | -9.2x |
| R&D budget | 64.2m | 113m | 193m | 187m | - | - | - |
| R&D % of revenue | 81 % | 87 % | 150 % | 93 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$4.5m | Series B | ||
$7.7m | Series C | ||
$50.0m | Series D | ||
| N/A | $100m | Series E | |
| N/A | $68.0m | Series E | |
$109m | Series F | ||
| N/A | $200m Valuation: $802m | IPO | |
$20.5m | Post IPO Debt | ||
$900m | Post IPO Convertible | ||
* | N/A | $85.0m | Post IPO Equity |
| Total Funding | CAD463m | ||
Related Content
Recent News about Pacific Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Pacific Biosciences
Edit
ACQUISITION by Pacific Biosciences Jul 2021
ACQUISITION by Pacific Biosciences Aug 2021
ACQUISITION by Pacific Biosciences Aug 2023